BioXcel Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview

BioXcel Therapeutics

07/08/2026 16:57

BioXcel Therapeutics Inc BTAI.OQ BTAI.O is expected to  show a rise in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026
The New Haven Connecticut-based  company is expected to report a 113.9% increase in revenue to $256.67 thousand from $120 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for BioXcel Therapeutics Inc is for a loss of 51 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $8.00, about 863.6% above its last closing price of $0.83
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.48
-0.82
-0.54
Beat
34.4
Dec. 31 2026
-0.69
-0.75
-0.58
Beat
22.7
Sep. 30 2025
-1.17
-1.18
-2.18
Missed
-85.1​
Jun. 30 2025
-1.90
-1.86
-2.45
Missed
-32
​​Mar. 31 2025
-8.45
-6.66
-1.50
Beat
77.5
Dec. 31 2024
-6.04
-6.42
-3.57
Beat
44.4​
Sep. 30 2024
-8.00
-8.67
-5.12
Beat
40.9
Jun. 30 2024
-11.12
-11.36
-3.36
Beat
70.4
This summary was machine generated August 7 at 15:57 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)